Fig. 1: High NSUN5 is associated with tumor progression in patients with HCC. | Oncogene

Fig. 1: High NSUN5 is associated with tumor progression in patients with HCC.

From: RNA 5-methylcytosine writer NSUN5 promotes hepatocellular carcinoma cell proliferation via a ZBED3-dependent mechanism

Fig. 1

A Pan-cancer analysis utilizing patient samples from TCGA database showed dysregulated NSUN5 expression in various cancer types, including HCC. B In patients with HCC, NSUN5 demonstrated significant upregulation in primary tumor tissues (n = 371) compared with normal tissues (n = 50). C NSUN5 exhibited significant upregulation in tumors with higher grades, with Grade 4 tumors showing a slight decrease in NSUN5 transcription (Grade 3 vs. Grade 1; Grade 3 vs. Grade 2). D NSUN5 expression significantly increased with the stage of HCC, except in Stage 4 HCC (Stage 2 vs. Stage 1; Stage 3 vs. Stage 1). E NSUN5 expression was higher in patients with TP53 gene mutations. F–H No significant correlations were observed between NSUN5 expression and patient age, gender, or race. I–L Patients with HCC exhibiting high NSUN5 expression experienced relatively poorer survival outcomes than those exhibiting low NSUN5 expression, as indicated by OS (HR = 1.47 [1.04–2.07], log-rank p = 0.028), RFS (HR = 1.69 [1.2–2.38], log-rank p = 0.0025), PFS (HR = 1.46 [1.08–1.97], log-rank p = 0.012), and DSS (HR = 2.13 [1.05–2.63], log-rank p = 0.028).

Back to article page